Inflammatory Bowel Disease Treatment Market Size Worth US$ 31.8 Bn by 2030
The global inflammatory bowel disease treatment market size is expected to be worth around US$ 31.8 billion by 2030, according to a new report by Vision Research Reports.
The global inflammatory bowel disease treatment market size was valued at US$ 20.3 billion in 2020 and is anticipated to grow at a CAGR of 5.8% during forecast period 2021 to 2030.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 31.8 Bn by 2030 |
| Growth Rate | CAGR of 5.8% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type; drug class, route of administration, distribution channel |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | AbbVie Inc.; Biogen; Johnson & Johnson Services Inc.; Amgen Inc.; UCB S.A.; Novartis AG; Takeda Pharmaceutical Company Limited; Merck & Co., Inc.; Pfizer Inc.; Lilly |
Growth Factors
rise in geriatric population, and favorable initiatives undertaken by regulatory bodies are anticipated to drive the market growth over the forecast period. For instance, in January 2020, the U.S. FDA allowed ABIVAX to conduct a phase 2B clinical trial of ABX464 on U.S. patients living with moderate-to-severe ulcerative colitis.
The rising prevalence of Crohn’s disease and ulcerative disease across the globe is expected to drive market growth over the forecast period. Moreover, increasing adoption of biologics for the treatment and the presence of strong pipeline drugs such as upadacitinib, risankizumab, tofacitinib, ustekinumab, and others is anticipated to boost the market growth in the coming years.
By Type Analysis
Crohn’s disease dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 61.3% in 2020. The segment is anticipated to maintain its dominance throughout the forecast period. High prevalence rate, increasing prescription rate of biologics, and high cost associated with Crohn’s disease treatment are factors driving the market for inflammatory bowel disease treatment.
The ulcerative colitis segment is anticipated to witness significant growth over the forecast period due to the high patient base and increasing approval of biologics for the treatment of ulcerative colitis.
By Drug Class Analysis
The TNF inhibitors segment dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 47.8% in 2020. The segment is anticipated to maintain its dominance during the forecast period.
The drug classes such as anti-integrin, aminosalicylates, and corticosteroids also have a significant share in the inflammatory bowel disease treatment market. Aminosalicylates is the first-line therapy for IBD treatment. However, JAK inhibitors are expected to grow at the fastest rate over the forecast period.
By Route of Administration Analysis
The injectable segment dominated the market for inflammatory bowel disease treatment and accounted for a revenue share of more than 75.0% in 2020. The dominance of the injectable segment is owing to the high efficacy of the injectable drugs.
The oral route of drug administration is estimated to witness the highest growth rate over the forecast period. The growth of this segment can be attributed to the approval of JAK inhibitors for IBD treatment and the presence of strong oral pipeline products for the treatment of inflammatory bowel disease.
By Distribution Channel Analysis
The hospital pharmacy segment dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of 46.8% in 2020. The segment is anticipated to dominate the market over the forecast period.
The online pharmacy segment is expected to grow at the fastest rate in the next 6 to 8 years. The growth of the online pharmacy segment can be attributed to the increase in online consultations from specialist doctors and the convenience and flexibility in online medicine purchasing.
By Regional Analysis
North America dominated the market for inflammatory bowel disease treatment and accounted for the largest revenue share of around 60.0% in 2020. The region is expected to experience lucrative growth over the forecast period.
In Asia Pacific, the market for inflammatory bowel disease treatment is anticipated to grow at the fastest rate over the forecast period. The increasing prevalence of Crohn’s disease and ulcerative colitis in the region, increasing prescription of biosimilars, and rising novel drug approval are expected to drive the market in the coming years.
Key Players
AbbVie Inc.
Biogen
Johnson & Johnson Services, Inc.
Amgen Inc.
UCB S.A.
Novartis AG
Takeda Pharmaceutical Company Limited
Merck & Co., Inc.
Pfizer Inc.
Lilly
Market Segmentation
By Type
Crohn's Disease
Ulcerative Colitis
By Drug Class
Aminosalicylates
Corticosteroids
TNF inhibitors
IL inhibitors
Anti-integrin
JAK inhibitors
Others
By Route of Administration
Oral
Injectable
Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Regional
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
India
China
Japan
Australia
South Korea
Singapore
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
Saudi Arabia
UAE
South Africa
The Inflammatory Bowel Disease Treatment market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Inflammatory Bowel Disease Treatment market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Inflammatory Bowel Disease Treatment market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Inflammatory Bowel Disease Treatment market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Inflammatory Bowel Disease Treatment market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Inflammatory Bowel Disease Treatment capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Inflammatory Bowel Disease Treatment by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Inflammatory Bowel Disease Treatment market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Inflammatory Bowel Disease Treatment market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Inflammatory Bowel Disease Treatment market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Inflammatory Bowel Disease Treatment industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
Inflammatory Bowel Disease Treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Inflammatory Bowel Disease Treatment market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Inflammatory Bowel Disease Treatment market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Inflammatory Bowel Disease Treatment market. These factors have benefited the growth of the global market for Inflammatory Bowel Disease Treatment. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Inflammatory Bowel Disease Treatment. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Inflammatory Bowel Disease Treatment are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Inflammatory Bowel Disease Treatment Market, By Type
7.1. Inflammatory Bowel Disease Treatment Market, by Type, 2021-2030
7.1.1. Crohn's Disease
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Ulcerative Colitis
7.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Inflammatory Bowel Disease Treatment Market, By Drug Class
8.1. Inflammatory Bowel Disease Treatment Market, by Drug Class, 2021-2030
8.1.1. Aminosalicylates
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Corticosteroids
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. TNF inhibitors
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. IL inhibitors
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Anti-integrin
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. JAK inhibitors
8.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Inflammatory Bowel Disease Treatment Market, By Distribution Channel
9.1. Inflammatory Bowel Disease Treatment Market, by Distribution Channel, 2021-2030
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Retail Pharmacy
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Online Pharmacy
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Inflammatory Bowel Disease Treatment Market, By Route of Administration
10.1. Inflammatory Bowel Disease Treatment Market, by Route of Administration, 2021-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Injectable
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Inflammatory Bowel Disease Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.1.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.1.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Type (2017-2030)
11.2.8.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.2.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.2.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Type (2017-2030)
11.3.8.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.3.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Type (2017-2030)
11.4.8.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.4.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Type (2017-2030)
11.5.6.2. Market Revenue and Forecast, by Drug Class (2017-2030)
11.5.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
11.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
Chapter 12. Company Profiles
12.1. AbbVie Inc.
12.1.1. Company Overview
12.1.2. Type Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Biogen
12.2.1. Company Overview
12.2.2. Type Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Johnson & Johnson Services, Inc.
12.3.1. Company Overview
12.3.2. Type Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Amgen Inc.
12.4.1. Company Overview
12.4.2. Type Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. UCB S.A.
12.5.1. Company Overview
12.5.2. Type Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Novartis AG
12.6.1. Company Overview
12.6.2. Type Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Takeda Pharmaceutical Company Limited
12.7.1. Company Overview
12.7.2. Type Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Merck & Co., Inc.
12.8.1. Company Overview
12.8.2. Type Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Pfizer Inc.
12.9.1. Company Overview
12.9.2. Type Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Lilly
12.10.1. Company Overview
12.10.2. Type Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers